Souhaitez-vous accéder aux communiqués récents ?

Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results

Seasoned biotechnology commercial leader will drive global growth strategy Commercial team further bolstered by promotions of James Vang and Jennifer Gelman to VP, Business Development and VP,...

Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference

Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Tools and Reagents: Global Markets" has been added to ResearchAndMarkets.com's offering.The global market for cell and gene...

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION...

Pluristyx and Solesis launch ready-to-use kit combining high-quality pluripotent cells and mRNA technology with proprietary transfection technology

Seamless Therapeutics announces research collaboration and licensing agreement with Eli Lilly for gene therapy for genetic hearing disorders

Dublin, Jan. 22, 2026 (GLOBE NEWSWIRE) -- The "Genome Editing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ResearchAndMarkets.com's...

Dublin, Jan. 15, 2026 (GLOBE NEWSWIRE) -- The "Genetic Modification Therapies Clinical Applications: Gene Therapies, Genetically Modified Cell Therapies, RNA Therapies and Gene Editing" has been...

Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook